Earnings Summary

Amphastar Pharmaceuticals Inc’s revenue jumped 4.58% since last year same period to $188.82Mn in the Q3 2024. On a quarterly growth basis, Amphastar Pharmaceuticals Inc has generated 3.52% jump in its revenue since last 3-months.

Amphastar Pharmaceuticals Inc’s net profit fell -17.86% since last year same period to $40.43Mn in the Q3 2024. On a quarterly growth basis, Amphastar Pharmaceuticals Inc has generated 6.54% jump in its net profits since last 3-months.

Amphastar Pharmaceuticals Inc’s net profit margin fell -21.46% since last year same period to 21.41% in the Q3 2024. On a quarterly growth basis, Amphastar Pharmaceuticals Inc has generated 2.91% jump in its net profit margins since last 3-months.

Amphastar Pharmaceuticals Inc’s price-to-earnings ratio after this Q3 2024 earnings stands at 14.49.

Amphastar Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at 1 - a 29.87% jump from last quarter’s estimates.

Amphastar Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at 1.

Amphastar Pharmaceuticals Inc’s earning per share (EPS) fell -16.52% since last year same period to 0.96 in the Q3 2024. This indicates that the Amphastar Pharmaceuticals Inc has generated -16.52% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amphastar Pharmaceuticals Inc’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amphastar Pharmaceuticals Inc’s return on equity (ROE) stands at 0.24.